Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chinese Journal of Clinical Medicine》 2018-04
Add to Favorite Get Latest Update

Research progress on adverse events in clinical treatment of anti-PD-1/PD-L1 antibodies

YU Min-cheng;HU Bo;FU Pei-yao;YANG Zhang-fu;TANG Wei-guo;SUN Hai-xiang;XU Yang;Department of Liver Surgery,Zhongshan Hospital,Fudan University;  
Although anti-PD-1/PD-L1 antibodies have been proved to be effective for a variety of cancers,meanwhile,it will also bring about immune-related adverse events(irAEs)peculiar to tumor immunotherapy.This article mainly reviews the adverse reactions induced by anti-PD-1/PD-L1 antibodies and corresponding countermeasures,as well as the impact of adverse events on the prognosis of patients and other related hot issues.
【Fund】: 国家自然科学基金(81572884 81372317)~~
【CateGory Index】: R730.51
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved